Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.
Abbott Laboratories ( ABT) Q4 2025 Earnings Call January 22, 2026 9:00 AM EST Good morning, and thank you for standing by.
Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript January 22, 2026 Abbott Laboratories reports earnings inline ...
People with spinal cord injuries often lose movement even though their brains still send the right signals. Researchers ...
In a first, this week the U.S. Food and Drug Administration approved a brain stimulation device designed to treat depression at home. The approval of the first such device for home depression ...